Diffuse Large B-cell Lymphoma Therapeutics Market Size, Share, Growth, and Forecast to 2029 | DataMIntelligence

May 24 22:36 2022
Diffuse Large B-cell Lymphoma Therapeutics Market Size, Share, Growth, and Forecast to 2029 | DataMIntelligence
DataM Intelligence
Global Diffuse Large B-cell Lymphoma Therapeutics Market is estimated to reach a high CAGR of 8% during the forecast period (2022-2029).

Market Overview

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL). DLBCL is an aggressive (fast-growing) NHL that affects B-lymphocytes. Lymphocytes are one type of white blood cell. B-cells are lymphocytes that make antibodies to fight infections and are an important part of the lymphatic system.


Download free sample @ https://www.datamintelligence.com/download-sample/diffuse-large-b-cell-lymphoma-therapeutics-market


Market Dynamics

The global diffuse large b-cell lymphoma Therapeutics Market growth is driven by the increasing incidence of DLBCL (Diffuse Large B-Cell Lymphoma), increasing preference for targeted therapies, and technological advancement coupled with advanced drug therapeutics.

Increasing preference for targeted therapies is expected to drive the growth in the forecast period

Targeted therapy is one of the most widely preferred methods for the treatment of diffuse large B-cell lymphoma, as targeted therapy is less toxic to healthy cells than chemotherapy. Targeted therapies act on specific molecular targets that are associated with cancer. Monoclonal antibodies, kinase inhibitors, immunomodulatory drugs, and nuclear export inhibitors are among the targeted therapies used for NHL. Rituximab is a targeted therapy that is used to treat a variety of B-cell NHL types. It works by focusing on a molecule known as CD20, which is found on the surface of both normal B cells and B-cell NHL cells. Ibrutinib is a targeted therapy that inhibits Bruton’s tyrosine kinase pathway. Mantle cell lymphoma, marginal zone lymphoma, and small lymphocytic lymphoma, as well as chronic lymphocytic leukemia and Waldenstrom macroglobulinemia, are among the B-cell lymphomas for which it has been approved.

Recent progress in molecular biology has led to a better understanding of the oncogenic drivers of DLBCL, resulting in the development of a large number of targeted therapies undergoing evaluation in phase I and II trials. Ibrutinib (Imbruvica), a targeted therapy approved by the FDA for use in multiple forms of lymphoma, has been tested in DLBCL to investigate if it affects the subtypes differently.


Market Segmentation:

By Drug Type

l Immuno and Targeted Drugs

l Others-Combination Drugs

By Route of Administration

l Intravenous Route

l Oral

By End-user

l Hospitals

l Cancer Centers

l Others


View full report @ https://www.datamintelligence.com/research-report/diffuse-large-b-cell-lymphoma-therapeutics-market


Competitive Landscape

The global diffuse large b-cell lymphoma Therapeutics Market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include. Hoffmann-La Roche Ltd, Novartis AG, Celltrion, Karyopharm Therapeutics, Kite Pharma, MorphoSys AG, AbbVie, CTI BioPharma, Seagen Inc., TG Therapeutics.

The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of wound care management devices globally. For instance, On February 19, 2019, The FDA granted Priority Review for elotuzumab vedotin in combination with bendamustine plus Rituxan (rituximab) (BR) for the treatment of patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).


Trending Topic’s

Chronic Lymphocytic Leukemia Therapeutics Market

Solid Tumor Therapeutics Market

Media Contact
Company Name: DataM Intelligence
Contact Person: Sai
Email: Send Email
Phone: +1 877 441 4866
Country: United States
Website: https://www.datamintelligence.com/research-report/diffuse-large-b-cell-lymphoma-therapeutics-market